1. Functional inversion of circadian regulator REV-ERBα leads to tumorigenic gene reprogramming.
- Author
-
Yang Y, Zhang X, Cai D, Zheng X, Zhao X, Zou JX, Zhang J, Borowsky AD, Dall'Era MA, Corey E, Mitsiades N, Kung HJ, Chen X, Li JJ, Downes M, Evans RM, and Chen HW
- Subjects
- Humans, Animals, Mice, Gene Expression Regulation, Neoplastic, Transcription Factors metabolism, Transcription Factors genetics, Hepatocyte Nuclear Factor 3-alpha metabolism, Hepatocyte Nuclear Factor 3-alpha genetics, Signal Transduction, Cell Line, Tumor, Neoplasms genetics, Neoplasms metabolism, Neoplasms pathology, Cell Cycle Proteins metabolism, Cell Cycle Proteins genetics, Nuclear Receptor Co-Repressor 1 metabolism, Nuclear Receptor Co-Repressor 1 genetics, Bromodomain Containing Proteins, Nuclear Receptor Subfamily 1, Group D, Member 1 metabolism, Nuclear Receptor Subfamily 1, Group D, Member 1 genetics, Circadian Rhythm genetics, Circadian Rhythm physiology, Carcinogenesis genetics
- Abstract
Profound functional switch of key regulatory factors may play a major role in homeostasis and disease. Dysregulation of circadian rhythm (CR) is strongly implicated in cancer with mechanisms poorly understood. We report here that the function of REV-ERBα, a major CR regulator of the orphan nuclear receptor subfamily, is dramatically altered in tumors in both its genome binding and functional mode. Loss of CR is linked to a functional inversion of REV-ERBα from a repressor in control of CR and metabolic gene programs in normal tissues to a strong activator in different cancers. Through changing its association from NCoR/HDAC3 corepressor complex to BRD4/p300 coactivators, REV-ERBα directly activates thousands of genes including tumorigenic programs such as MAPK and PI3K-Akt signaling. Functioning as a master transcriptional activator, REV-ERBα partners with pioneer factor FOXA1 and directly stimulates a large number of signaling genes, including multiple growth factors, receptor tyrosine kinases, RASs, AKTs, and MAPKs. Moreover, elevated REV-ERBα reprograms FOXA1 to bind new targets through a BRD4-mediated increase in local chromatin accessibility. Pharmacological targeting with SR8278 diminishes the function of both REV-ERBα and FOXA1 and synergizes with BRD4 inhibitor in effective suppression of tumorigenic programs and tumor growth. Thus, our study revealed a functional inversion by a CR regulator in driving gene reprogramming as an unexpected paradigm of tumorigenesis mechanism and demonstrated a high effectiveness of therapeutic targeting such switch., Competing Interests: Competing interests statement:The authors declare no competing interest.
- Published
- 2024
- Full Text
- View/download PDF